Hence, in the present study, we hypothesize that SIRT-1-mediated inhibition of the NOTCH-1 receptor can be an effective treatment to overcome the disease progression in NAFLD/NASH. This evidence concerns the gene NOTCH1 and metabolic dysfunction-associated steatotic liver disease.